Professor Robin Feldman is interviewed by Vice Magazine, on price hikes in the pharmaceutical industry and her research on patent trolling.

Tweet about this on TwitterShare on LinkedInShare on FacebookShare on Google+Email this to someone

“There’s a gold rush for profit in areas dominated by patents. That includes tech, and it also includes pharma—drug companies. The gold rush is encouraging business behaviors that may not be in the public interest.”

“I think it really is the popularization of—or emergence of—the patent-trolling model. That is: invention used primarily for licensing revenue rather than making products. We want tech companies and drug companies to be innovating, creating new products for the benefits of society. We don’t want the most creative work at a company to be happening in the legal department.”

The full interview can be found here.

Tweet about this on TwitterShare on LinkedInShare on FacebookShare on Google+Email this to someone

Comments are closed.